WATERTOWN, Mass.–(BUSINESS WIRE)– Exo Therapeutics, Inc.a pioneer in the discovery and development of small molecules capable of reprogramming protein targets by binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery, and of Catherine Scholz, PharmD, as Senior Vice President, Program Management.

“Drs. Ioannidis and Scholz are both dedicated leaders and great additions to our team as we grow our pipeline this year while continuing to leverage our ExoSight™ discovery platform,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Dr. Ioannidis has a strong track record of bringing new candidates into the clinic and experience that spans from early discovery to clinical development. Dr. Scholz has played a key role in the development and approval of several innovative drugs. Welcome to the team!”

“Exosites hold tremendous potential that can allow us to greatly expand the diversity of targets we can pursue in drug discovery and, therefore, the potential benefits we can deliver to patients,” said Dr. Ioannidis. “I look forward to leading the company’s discovery efforts and am excited to expand the horizons of this emerging approach.

“I am thrilled to join Exo’s committed and passionate team of scientists and drug developers and look forward to championing a high-performance team culture to advance breakthrough therapies,” said Dr. Scholz. .

Dr. Ioannidis has over 20 years of experience in oncology, neuroscience and inflammatory drug development, with a particular focus on early discovery through to delivery of IND. Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics, where he led the company’s drug discovery group focused on innate immune system therapies. Dr. Ioannidis has also held positions of increasing responsibility at H3 Biomedicine, FORMA Therapeutics and AstraZeneca R&D. Dr. Ioannidis received his PhD in Synthetic Organic Chemistry from Imperial College of Science, Technology and Medicine, University of London and completed his postdoctoral fellowship at Harvard University.

Dr. Scholz brings over 20 years of experience in program management, portfolio strategy and clinical pharmacology. She played a key role in the development and approvals of vedolizumab, brentuximab vedotin and estradiol valerate/dienogest. Prior to joining Exo Therapeutics, Dr. Scholz was Vice President of Clinical Development at H3 Biomedicines, a subsidiary of Eisai Co., Ltd. Additionally, Dr. Scholz has held leadership positions of increasing responsibility at Kura Oncology, EMD Serono, Millennium Pharmaceuticals, and Bayer Schering Pharma. Dr. Scholz received her Doctor of Pharmacy degree from Rutgers University and completed postgraduate training in clinical pharmacology at the University of Texas, MD Anderson Cancer Center.

About Exo Therapeutics

Exo Therapeutics is a small molecule drug discovery and development company with pioneering technology to target intractable pharmaceutical targets. Leveraging the company’s ExoSight^MT platform, Exo is developing an extensive pipeline of potent drug candidates that bind to exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s world-class team of researchers is unlocking breakthrough therapeutic avenues in oncology, inflammation and a wide range of other diseases. For more information, visit www.exo-therapeutics.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220517005248/en/